Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations (Q38753738)

6 September 2017

title

Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations (English)

1 reference

6 September 2017

Amy G Groom

1 reference

6 September 2017

Tallal Younis

series ordinal

1 reference

6 September 2017

publication date

29 February 2016

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

245-255

1 reference

Endogenous hormones and breast cancer risk

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Tamoxifen for breast cancer prevention: a framework for clinical decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Chemoprevention: drug pricing and mortality: the case of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

The benefits and costs of tamoxifen for breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2016.1159514

10.1586/14737167.2016.1159514

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference